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Summary
 Background Stomach cancer is the 8th most common cause of cancer death, with median age 
of diagnosis 70 years for men and 74 years for women. Surgical resection is still 
the method of choice and surgical trials are focused on identifying prognostic 
factors for groups of patients undergoing curative surgery.
 Aim The aim of our retrospective study was an analysis of prognostic factors in a group 
of patients with gastric cancer.
 Materials/Methods We retrospectively analyzed a group of 248 patients with gastric cancer. Clinical 
and histological parameters were collected and then correlated with each anoth-
er and with survival time using statistical parametric and nonparametric meth-
ods. Survival probability was estimated by Kaplan-Meier method. Statistical sig-
niﬁ cance of prognostic factors depending on survival time was assessed by the 
Cox nonparametric proportional hazard regression model.
 Results Univariate analysis showed signiﬁ cance of the following parameters: weight loss 
of more than 10 kg, tumour size, histological type of tumour, lymph node involve-
ment, stage at the time of diagnosis and type of operation. Multivariate analysis 
showed that weight loss of more than 10 kg, T2 tumour size, lymph metastases, 
total gastrectomy and ﬁ nally curative operation were independent prognostic 
factors of survival.
 Conclusions Taking our data together we conclude that: (i) lymph node metastasis is a sig-
niﬁ cant prognostic factor with poor prognosis, (ii) type of operation is a signif-
icant prognostic factor of survival, (iii) we conﬁ rmed the inﬂ uence of T2 depth 
of invasion for patients’ overall survival, (iv) weight loss of more than 10 kg dis-
plays a statistical correlation with survival time and worse prognosis, (v) param-
eters connected with complications after surgical procedures have no inﬂ uence 
on survival time in the examined group.
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BACKGROUND
Rates of stomach cancer are declining rapidly in 
Poland as in many parts of the world, especially 
in developed countries due to better living condi-
tions and dietary changes. But we have to remem-
ber that it is still the eighth most common cause 
of cancer death. The incidence in Poland is 18.6 
for males and 9.7 for females per 100,000 [1], in 
Europe 12–15 per 100,000, in the USA 5.2 per 
100,000 and 93 per 100,000 in Japan [2,3]. The 
median age of diagnosis is 70 years for men and 
74 years for women, with twice as high incidence 
in men as in women and increased with age. The 
geriatric population is expanding, and hence clin-
ical decision making is often confused by effects of 
aging [2,4]. Complete management of cancer in 
this population, and its eventual outcome, could 
be improved by specialists with experience in on-
cogeriatric management. The anatomic location of 
gastric cancer is changing. A 4–5% increase in in-
cidents of proximal or cardiac cancers per year in 
Europe has been noted. This rate parallels the in-
crease in distal oesophageal adenocarcinomas, sug-
gesting a relationship with bile or alkaline reﬂ ux 
[5]. These cancers tend to have a worse prognosis 
secondary to the later onset of diagnosis and the 
more extensive lymph node drainage that involves 
the mediastinal, abdominal, and retroperitoneal 
lymphatics [6]. Proximal cancers have been sub-
classiﬁ ed by Siewert and Stein based on location 
of the majority of tumour mass [7]. Several studies 
have also noted differences between oesophageal 
and proximal gastric cancer. Proximal gastric can-
cers are associated with H. pylori infections and of-
ten have inﬂ ammation, whereas oesophageal can-
cers are rarely associated with H. pylori and have 
much less inﬂ ammation. Distal gastric cancers, 
on the other hand, have continued to decrease 
in incidence. This decrease may be due to better 
living conditions, better dietary habits, and erad-
ication of H. pylori. Distal cancers are seen most 
commonly in Asia [8].
Surgical resection is still the treatment of choice 
for gastric cancer. The goal of a surgical cure re-
quires complete resection to R0 status, as the stage 
of disease is the most important predictor of out-
come. According to the literature data, 20–30% 
of patients in Europe present inoperable cancer 
secondary to metastatic disease. Of the remain-
ing 75% progressing to surgery, 20% of patients 
have unresectable cancer at the time of surgery, 
25% have cancer with positive microscopic mar-
gins (R1) and 20–30% have a curative procedure 
performed [9]. Surgery may be required for cura-
tive procedures determined by the incision need-
ed, the extent of gastric/oesophageal resection 
needed and for palliative secondary to bleeding 
and obstruction and may even be offered as an op-
tion in prolonging life. The great majority of gas-
tric cancers that recur and metastasize do so ﬁ rst 
in the regional lymph nodes before spreading. A 
D2 resection includes N1 lymph nodes in the im-
mediate perigastric region and nodes along the ce-
liac access and its named branches and along the 
middle colic, superior mesentery artery and peri-
aortic nodes. D2 resection has been recommend-
ed by the American Joint Committee on Cancer 
manual [10]. The majority of surgeons in the USA 
and many in Europe excise the N1 lymph nodes. 
Several studies in Europe and in the USA, however, 
have failed to show any signiﬁ cant impact on sur-
vival and have even shown an increase in perioper-
ative morbidity and mortality with more extensive 
lymph node resections [11–18]. Survival data are 
varied in the literature. According to studies in the 
USA and Europe the survival rate at 5 years for T1 
with no positive node was 93%; for T2, 84%; and 
for T3, 52%. Overall survival for stage IA is 78%; 
for stage IB, 58%; for stage II, 34%; for stage IIIA, 
20%; for stage IIIB, 18% and for stage IV 7% over 5 
years. Survival for R0 is 35% and increases to 79% 
if the cancer is node negative [19,20].
AIM
Surgical trials have focused on identifying prog-
nostic factors. Some clinicopathologic features 
are proposed as a simple tool for prognostic 
grouping of patients undergoing curative surgery 
[21,22]. This study analyzed the clinicopathologic 
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features and prognostic factors that affect the 
survival rate of patients with gastric carcinoma. 
The aim of this retrospective study was an anal-
ysis of prognostic factors in a group of patients 
with gastric cancer.
MATERIALS AND METHODS
The series included 248 cancer patients oper-
ated on between 1995 and 2001 in the Second 
Oncological Surgery Ward in the Wielkopolska 
Oncology Centre in Poznań.
The average age of the examined patient group 
was 60.7 years old (age 24–87, standard deviation 
12.4). The group included 85 women (34.4%) 
and 162 men (65.6%). The clinicopathologic fea-
tures of these patients were reviewed retrospec-
tively, including the following information: age, 
gender, family history, blood group, weight loss of 
more than 10 kg and previous gastric operation. A 
histological evaluation was performed according 
to the AJCC Cancer Staging Manual. According 
to the grade of anaplasia, 31 tumours were well 
differentiated, 70 moderately differentiated and 
104 poorly differentiated. Radical total gastrec-
tomy was deﬁ ned as all gross lesions removed as 
judged by the surgeon (R0, R1) and curative re-
section was deﬁ ned as radical total gastrectomy 
and the resection margins were histologically 
normal (R0: no residual tumour). Survival rates 
were obtained from hospital records.
Statistical analysis was performed using univari-
ate logistic regression. We used Shapiro-Wilk and 
Variables 0 1 p Value
Median age, years (range),
Std. Dev.
60.7 (24–83)
Std. Dev. 12.5 
60.2 (28–87)
Std. Dev. 13.2 NS
Gender
Female  42 35.0%  29 34.1%
NS
Male  78 65.0%  56 65.9%
Family gastric cancer
 9 7.5%  8 9.4%
NS
 111 92.5%  77 90.6%
A Rh positive
 40 33.3%  26 30.6%
NS
 80 66.7%  59 69.4%
Weight loss of more than 10 kg 
 65 54.1%  25 29.4%
p=0.0031*
 49 45.9%  56 70.6%
Previous gastric operation 
 13 10.8%  10 11.8%
NS
 107 89.2%  75 88.2%
Table 1. Clinical characteristics of patients.
0 – death; 1 – survived; * Statistically signifi cant; NS – Non-signifi cant.
Clinical staging
IA T1N0M0  0 0.0%  11 5.4%
IB T1N1M0
 T2N0M0
 1 0.48%  19 9.26%
II T1N2M0
 T2N1M0
 T3N0M0
 15 7.3%  21 10.2%
IIIA T2N2M0
 T3N1M0
 T4N0M0
 25 12.2%  16 7.8%
IIIB T3N2M0  10 4.9%  5 2.4%
IV M1N3
 T4N1
 T4N2
 81 39.5%  1 0.48%
Depth of invasion.
T1  13 5.5%  4 1.7%
T2  18 7.5%  34 14.3%
T3  43 18.1%  34 14.3%
T4  46 19.3%  1 0.4%
IV M1,N3
 T4N1
 T4N2
 44 18.5%  1 0.4%
Table 2. Clinicopathological characteristics of patients.
0 – death; 1 – survived.
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Lilliefors test and then Student’s t-test, c2 square 
test with Yates’ modiﬁ cations and Fisher’s exact 
test. The Mann-Whitney U-test served as the non-
parametric method. The statistical signiﬁ cance of 
analyzed factors depending on patient survival or 
death was assessed. Survival probability was esti-
mated using the Kaplan-Meier method. Then, clin-
ical, histopathological and immunohistochemical 
data showing statistical signiﬁ cance were correlat-
ed with survival time. The statistical signiﬁ cance 
of prognostic factors depending on survival time 
was assessed by the Cox nonparametric propor-
tional hazard regression model. A p value <0.05 
was considered statistically signiﬁ cant for all pro-
cedures. The statistical analysis was performed us-
ing Statistica for Windows release 6.0.
RESULTS
Among the 275 patients with gastric cancer, 27 
failed to be followed up, with follow-up rate of 
90.1%. Clinical and histopathological data are 
presented in Tables 1, 3 and 4. The grade of 
advance of malignancy according to TNM is 
presented in Table 2. Out of 248 patients ad-
mitted to the Second Division of Oncological 
Surgery in the Wielkopolska Oncology Centre in 
Poznań complete data were collected from 205 
patients. Age of patients at the time of the ini-
tial diagnosis ranged from 24 to 87 with mean 
age of 60.7 years. The group included 85 wom-
en (34.4%) and 162 men (65.6%); the gender 
ratio was 0.53:1.
Variables 0 1 P Value
Depth of invasion Mann-Whitney U Test
U Z p-level
T1  48.0000  –3.2281* p=0.0012*
T2  36.0000  –4.0931* p=0.0000*
T3  62.0000  –1.7781 NS
T4  60.0000  2.1654* p=0.0303*
Histological type
G1 well
 12 10.0%  19 22.4% p=0.0150*
 108  66
G2 moderately  38 31.7%  32 37.6% NS
 82  53
G3 poorly diff erentiated  70 58.3%  34 40.0% p=0.0097*
 50  51
Intestinal type  46 48.4%  31 43.1% NS
 49  41
Diff used type  21 22.1%  27 37.5% p=0.0295*
 74  45
Mixed type  28 29.5%  14 19.4% p=0.0538* 
 67  68
Sarcoma  0  2 2.4% NS
 120  83
Carcinoid  1 0.8%  0 0.0% NS
 119  85
Lymphoma  7 5.9%  5 5.9% NS
 113  85
Table 3. Histological classifi cation of tumours.
0 – death; 1 – survived; * Statistically signifi cant; NS – Non-signifi cant.
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Median survival time according to Kaplan-Meier was 
15.9 months; lower quartile (25th percentile) was 4.0 
months. The survival curve is presented in Figure 1. 
Next the following parameters were analyzed: age, 
gender, family history, blood group, weight loss of 
more than 10kg, previous gastric operation, depth 
of invasion using T parameter, histological type ac-
cording to grade, the Lauren classiﬁ cation scheme 
with three main subgroups for gastric cancer (in-
testinal, diffuse and mixed type), pTNM classiﬁ ca-
tion, type of surgery and complications.
The statistical signiﬁ cance of analyzed factors 
depending on patient survival or death was as-
sessed. Results are presented in Tables 1, 3–6. 
Then, statistical signiﬁ cance of prognostic fac-
tors depending on survival time was assessed by 
the Cox nonparametric proportional hazard re-
gression model. The ﬁ nal results are presented 
in Table 7.
Univariate analysis showed that weight loss of 
more than 10kg (p=0.0031); T1 (p=0.0012), T2 
(p=0.0000), T4 (p=0.0303) tumour size; histo-
logical type according to grade G1 (p=0.0150), 
G3 (p=0.0097); diffused (p=0.0295) and mixed 
(p=0.0538) type according to the Lauren clas-
siﬁ cation scheme; extent of lymph nodal in-
volvement (p=0.0000), peritoneal dissemination 
(p=0.0000), stage at the initial diagnosis T1N0M0 
(p=0.0012), T2N0M0 (p=0.0000), T4N1M0 
(p=0.0303), T4N2M1 (p=0.0329); synchronous 
metastases (p=0.0000), metachronous metas-
tases (p=0.0000), radical (p=0.0000), palliative 
(p=0.0017), curative total gastrectomy (p=0.0000) 
were signiﬁ cant for examined patients with gas-
tric cancer. Multivariate analysis showed that 
weight loss of more than 10 kg (p=0.0446), T2 
tumour size (p=0.0401), lymph node metastases 
(p=0.0189), total gastrectomy (p=0.0253), and 
curative operation (p=0.0005) were independent 
Variables 0 1 p Value
N (+)
 95 79.2%  39 45.9%
p=0.0000*
 25  46
Peritoneal dissemination
 47 39.2%  1 1.2%
p=0.0000*
 73  84
Clinical staging
Mann-Whitney U Test
U Z p-level
T1N0M0  48.0000  –3.2282* p=0.0012*
T1N1M0  71.0000  –0.6759 NS
T2N0M0  36.0000  –4.0931* p=0.0000*
T2N1M0  264.0000  –0.5794 NS
T2N2M0  82.0000  0.8660 NS
T3N0M0  62.0000  –1.7781 NS
T3N1M0  311.0000  0.7958 NS
T3N2M0  135.0000  0.8451 NS
T3N1M1  14.0000  0.9847 NS
T4N1M0  60.0000  2.1654* p=0.0303*
T4N2M0  54.0000  1.4041 NS
T4N2M1  49.5000  2.1330* p=0.0329*
Synchronous metastases
 30 25.0%  2 2.4%
p=0.0000*
 90  83
Metachronous metastases
 19 15.8%  2 2.4%
p=0.0000*
 101  83
Table 4. Clinicopathological features of gastric carcinoma.
0 – death; 1 – survived; * Statistically signifi cant; NS – Non-signifi cant.
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prognostic factors of survival. The parameters 
connected with complications showed no statis-
tical signiﬁ cance in the examined group of pa-
tients.
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Figure 1. Graph of survival times vs. cumulative proportion surviving according to Kaplan-Meier method.
Note: Weights: 1=1., 2=1./V, 3=N(I)*H)I)
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Figure 1. Graph of survival times vs. cumulative proportion surviving according to Kaplan-Meier method.
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DISCUSSION
The goal of primary successful treatment is surgi-
cal cure complete resection to R0 status. Survival 
for R0 is 35% and increases to 79% if the cancer 
is node negative [19, 20]. The studies showed 
that 25% of patients died during a period of 4.0 
months and 50% lived longer than 15.9 months. 
In the whole group of patients, 1, 3 and 5 year 
survival was 57%, 34% and 28%, respectively. 
Survival data vary in the literature according to 
country of origin, differences in biology, extent 
of resection, and clinical stage of the disease. The 
prognosis of gastric cancer remains grim, with 
a 5-year relative survival of 25% in France and 
not much more than 21% in Europe [23,24]. In 
Japan, improvement in survival has been shown 
with more extensive lymphadenectomy, so it has 
been attributed to more intense pathologic as-
sessment of lymph nodes. There may be a differ-
ence in interpreting pathology as many Western 
patients may be understaged. A D2 resection is 
recommended due to identiﬁ cation of 20% in-
cidence of skip metastasis to D2 nodes, but sur-
vival was slightly improved only for patients who 
had T3 disease and were node negative. Several 
studies have shown that the total number of dis-
sected lymph nodes had no inﬂ uence on surviv-
al, whereas patients with a higher ratio of meta-
static/dissected lymph nodes were characterized 
by signiﬁ cantly poorer prognosis [25]. In the an-
alyzed group of patients 65.4% lymph node me-
tastases were found. It is known that the chance 
of positive nodes is <4% for a T1a, 23% for a 
T1b, 44% to 50% for a T2 and 64% for a T3 le-
sion [26]. In our study univariate analysis showed 
that lymph node metastases were signiﬁ cant prog-
nostic factors (p=0.0000). Multivariate analysis 
conﬁ rmed that nodal involvement was a signiﬁ -
cant prognostic factor of survival in the analyzed 
group (p=0.0189). This is probably one of the 
most predictive negative factors connected with 
low overall survival.
The main signiﬁ cant prognostic variable is lymph 
node involvement [27–29] followed by tumour 
depth [27,29]. Risk of lymph node spread can be 
predicted by tumour depth. In Western countries 
and in the USA early gastric cancer is diagnosed 
in 15–20%, while in Japan as much as 60% [9]. 
Variables 0 1 p Value
Total gastrectomy
 76 63.3%  80 94.1%
p=0.0000*
 44  5
Subtotal gastrectomy
 1 0.8%  3 3.5%
NS
 119  82
Radical total gastrectomy
 57 47.5%  78 91.8%
p=0.0000*
 63  7
Palliative total 
gastrectomy
 19 15.8%  2 2.4%
p=0.0017*
 101  83
Laparotomy
 43 35.9%  1 1.2%
p=0.0000*
 77  84
Resectability
  64.1%   98.8%
  35.9%   1.2%
Thoracotomy
 4 3.3%  0 0.0%
NS
 116  85
Splenectomy
 10 8.3%  13 15.3%
NS
 110  72
Curative operation
 58 48.3%  82 96.5%
p=0.0000*
 62  3
Table 5. Surgical procedures..
0 – death; 1 – survived; * Statistically signifi cant; NS – Non-signifi cant.
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In Poland the number reaches only a few per-
cent. In our material early gastric cancer T1 was 
found in 17 patients (7.2%), ﬁ rst clinical stage 
was found in 11 patients (5.4%). The remain-
ing 95.6% of patients had advanced carcinomas. 
Univariate analysis of our material showed that 
invasive depth T1 (p=0.0012), T2 (p=0.0000), 
T4 (p=0.0303) is a signiﬁ cant prognostic factor. 
Multivariate analysis conﬁ rmed the inﬂ uence 
of T2 depth of invasion (p=0.0401) for patient 
overall survival. Komatsu et al. [30] reported that 
analysis of cases with curative operations showed 
that lymphatic invasion and lymph node metas-
tasis were signiﬁ cant prognostic factors in pa-
tients with T2 gastric cancer. Further examina-
tion by multivariate analysis demonstrated that 
pN2 or higher as classiﬁ ed by both the JCGC 
(Japanese Classiﬁ cation of Gastric Cancer) and 
the TNM lymph node staging systems was a pre-
dictor of poor prognosis. The authors conclud-
ed that lymph node staging was the most relia-
ble prognostic factor for T2 gastric cancer. Close 
follow-up should be required for patients with 
stage pN2 or higher gastric cancer. Long-term 
follow-up should be required for these cancers 
in particular.
Out of a total of 205 analyzed surgical interven-
tions, curative operation was performed in 140 
patients. Gastrectomy in combination with lym-
phadenectomy was performed as a curative mo-
dality for localized gastric cancer in our group 
of gastric cancer patients. In the group of pa-
tients with gastric adenocarcinoma in the upper 
third of the stomach the extent of lymphadenec-
tomy should be tailored to tumour location. 
Lymphadenectomy might include the lateroaor-
tic lymph nodes for advanced gastric cancer in 
Variables 0 1 p Value
Dehistentio vulneris
 3 3.9%  2 2.4%
NS
 74  80
Bleeding (requiring revisions)
 2 2.6%  0 0.0%
NS
 75  82
Wound infection
 8 10.4%  6 7.3%
NS
 66  76
Anastomotic leakage
 5 6.5%  0 0.0%
NS
 72  82
Abscess of the abdomen
 0 0.0%  2 2.4%
NS
 77  80
General complications
Abscess of the lungs
 1 1.3%  1 1.2%
NS
 76  81
Pneumonia
 9 11.7%  6 7.3%
NS
 68  76
Cardiorespiratory complications
 5 6.5%  0 0.0%
NS
 72  82
Pulmonary embolism
 1 1.3%  0 0.0%
NS
 76  82
7-day perioperative mortality
 3 1.5%
 202
30-day mortality
 14 6.8%
 191
Table 6. Complications.
0 – death; 1 – survived; NS – Non-signifi cant.
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the upper third of the stomach and the supra-
diaphragmatic and lower paraesophageal nodes 
for tumours extending to the oesophagus [31]. 
Several studies have demonstrated no survival 
difference in type of resection as long as mar-
gins are negative [32,33]. Randomized control-
led trials are needed to verify these indices. A 
sentinel node biopsy has been proposed for early 
gastric cancer when a local excision may be per-
formed. The sentinel node technique should be 
performed to identify unsuspected patterns of 
drainage and to allow for a more thorough path-
ologic assessment of the ﬁ rst sentinel node. No 
clinical trials have been performed to give deﬁ n-
itive recommendations, and critics of this tech-
nique note the extensive drainage to the celiac 
axis, liver, mediastinum and retroperitoneal ba-
sins [34]. In our series univariate analysis showed 
that type of operation was signiﬁ cant but only cur-
ative or total gastrectomy were signiﬁ cant prog-
nostic factors of survival in multivariate analysis. 
The p value was 0.0005 and the relative risk was 
1.7027 when the observed value was curative re-
section. Multivariate analysis showed that total 
gastrectomy was a negative independent prog-
nostic factor of survival in our group with p value 
0.0253 and relative risk 5.0013. Total gastrectomy 
was the procedure most frequently performed in 
our patients (76%) as a curative (89.7%) or pal-
liative (11.3%) operation. Poor outcomes for pa-
tients with palliative treatment and worst surviv-
al rate were the most negative predictive factors 
for this group.
Weight loss of more than 10kg (p=0.0446) showed 
a statistical correlation with survival time in our 
study. This is characteristic for advanced cancers 
but we did not ﬁ nd any papers analyzing that as 
an independent prognostic factor. Many authors 
conﬁ rmed that pain is the ﬁ rst symptom [35] and 
0 – death; 1 – survived; * Statistically signifi cant; NS – Non-signifi cant.
Statistical survival analysis Dependent variable: survival – (months)χ2 = 141.129 ; df = 18 ; p = 0.0000 (p<0.05) 
Prognostic factor Beta Statistical error Exponent beta (relative risk) Wald statistic p
Weight loss of more than 10 kg  0.4254  0.2118  1.5303  4.0315 0.0446*
T1  –3.4727  1.8939  0.0310  3.3622 NS
T2  –0.6422  0.3129  0.5260  4.2124 0.0401*
T4  0.4038  0.2621  1.4975  2.3729 NS
Histological type G1 well  –0.1543  0.3650  0.8570  0.1786 NS
G3 poorly diff erentiated  –0.2114  0.2160  0.8094  0.9574 NS
Diff used type  –0.0530  0.6040  0.9482  0.0077 NS
Mixed type  0.4491  0.4726  1.5669  0.9030 NS
N (+)
N (–)  1.06910  0.4555  2.9127  5.5073 0.0189*
Peritoneal dissemination  0.4198  0.2903  1.5216  2.0898 NS
T1N0M0  2.0575  2.1179  7.8265  0.9437 NS
T2N0M0  –1.8715  1.2929  0.1538  2.0953 NS
T4N1M0  0.2955  0.5292  1.3438  0.3118 NS
T4N2M1  0.7044  1.0521  2.0226  0.4482 NS
Synchronous metastases  0.1218  0.2472  1.1295  0.2428 NS
Metachronous metastases  0.2071  0.3242  1.2301  0.4078 NS
Total gastrectomy  –0.7667  0.3428  0.4645  5.0013 0.0253*
Curative operation  0.5322  0.1533  1.7027  12.0117 0.0005*
Table 7. Statistical signifi cance factors depending on survival time assessed by Cox nonparametric proportional hazard regression model.
Rep Pract Oncol Radiother, 2006; 11(5): 235-246 Kycler W et al – Prognostic factors of stomach cancer in a Polish group of patients
243
that anaemia as an inaugural event is increasing 
signiﬁ cantly [36]. Symptomatic ﬁ ndings in the ear-
ly stage of disease are relatively vague and nonspe-
ciﬁ c. The increased use of proton pump inhibitors 
may contribute to later time of diagnosis due to 
resolution of common vague symptoms [37].
Several authors have reported on other prognos-
tic factors by multivariate analysis, such as histo-
logical type with well, moderate or poor differ-
entiation [38]. By histological type, we found 
signiﬁ cance in univariate analysis between pa-
tient survival or death for histologically good (G1: 
p=0.0150) and poor (G3: p= 0.0097) differentia-
tion. Nakamura et al. [39] analyzed the histologi-
cal types of early gastric cancer in elderly patients, 
and found that 45.5% of early gastric carcinomas 
were well differentiated. Other studies have re-
ported similar results but there were any signiﬁ -
cance with survival rate/none with a signiﬁ cant 
effect on survival [40]. We did not ﬁ nd any sim-
ilar correlations in our study.
In our study the Lauren scheme was analyzed as 
histological parameters. The intestinal type typ-
ically involves the distal stomach and the gland-
like structures that mimic intestinal glands. The 
diffuse or signet ring type is more frequent-
ly found in the proximal stomach, and the tu-
mours are more poorly differentiated and lack 
glandular structures. The intestinal type is more 
commonly seen in Asian patients and the elder-
ly, the second one more commonly in Western 
cultures, younger patients and individuals with 
blood type A [26,41].
Many patients present distant metastases or di-
rect invasion of organs, obviating the possibility 
of complete resection. Metastatic or unresecta-
ble upper gastrointestinal malignancies are incur-
able but do beneﬁ t from palliative surgery and 
chemotherapy [42]. The combination of chem-
oradiotherapy and palliative surgery has been 
reported to have positive results on overall sur-
vival [43]. In our study signiﬁ cantly worse prog-
nosis was found in univariate analysis for patients 
with synchronous or metachronous metastases 
(p=0.0000 and p=0.0000 respectively). There is 
no correlation with survival rates.
The remaining parameters such as complications 
showed no statistically signiﬁ cant inﬂ uence on 
patient survival and did not display any statisti-
cal signiﬁ cance on patient survival. Two trials in 
Europe (Dutch trial [18] and MRC trial [16]) 
proved that postoperative mortality will not af-
fect the results in the long term. Following great 
improvements in surgical techniques, postoper-
ative care and measures of digestive tract recon-
struction may increase the risk of general com-
plications [44].
CONCLUSIONS
We conclude that: (i) lymph node metastasis is a 
signiﬁ cant prognostic factor with poor prognosis 
for gastric cancer patients, (ii) in our series mul-
tivariate analysis showed that curative and total 
gastrectomy are respectively positive and nega-
tive signiﬁ cant prognostic factors of survival, (iii) 
our analysis conﬁ rms the inﬂ uence of T2 depth 
of invasion for patients’ overall survival, (iv) one 
clinical symptom, weight loss of more than 10kg, 
displays a statistical correlation with survival time 
and worse prognosis in a group of patients with 
gastric cancer, (v) the parameters connected with 
complications after the surgical procedures do 
not display any signiﬁ cant inﬂ uence on survival 
time in the examined group.
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